169 related articles for article (PubMed ID: 36637483)
1. New Life of Topoisomerase I Inhibitors as Antibody-Drug Conjugate Warheads.
Pommier Y; Thomas A
Clin Cancer Res; 2023 Mar; 29(6):991-993. PubMed ID: 36637483
[TBL] [Abstract][Full Text] [Related]
2. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Kinneer K; Wortmann P; Cooper ZA; Dickinson NJ; Masterson L; Cailleau T; Hutchinson I; Vijayakrishnan B; McFarlane M; Ball K; Davies M; Lewis A; Huang Y; Rosenbaum AI; Yuan J; Chesebrough J; Anderton J; Monks N; Novick S; Wang J; Dimasi N; Christie RJ; Sabol D; Tosto FA; Wallez Y; Leo E; Albertella MR; Staniszewska AD; Tice DA; Howard PW; Luheshi N; Sapra P
Clin Cancer Res; 2023 Mar; 29(6):1086-1101. PubMed ID: 36355054
[TBL] [Abstract][Full Text] [Related]
3. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
4. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells.
Guha Majumdar A; Shree S; Das A; Kumar BK; Dey P; Subramanian M; Patro BS
Eur J Med Chem; 2023 Oct; 258():115598. PubMed ID: 37406384
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.
Weng W; Meng T; Zhao Q; Shen Y; Fu G; Shi J; Zhang Y; Wang Z; Wang M; Pan R; Ma L; Chen C; Wang L; Zhou B; Zhang H; Pu J; Zhang J; Hu YP; Hua G; Qian Y; Liu SH; Hu W; Meng X
Cancer Discov; 2023 Apr; 13(4):950-973. PubMed ID: 36693125
[TBL] [Abstract][Full Text] [Related]
7. Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A; Pommier Y
Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
[TBL] [Abstract][Full Text] [Related]
8. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Anderson MG; Zhang Q; Rodriguez LE; Hecquet CM; Donawho CK; Ansell PJ; Reilly EB
BMC Cancer; 2021 Jun; 21(1):681. PubMed ID: 34107902
[TBL] [Abstract][Full Text] [Related]
9. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab Deruxtecan: First Approval.
Keam SJ
Drugs; 2020 Apr; 80(5):501-508. PubMed ID: 32144719
[TBL] [Abstract][Full Text] [Related]
11. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
12. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology.
Ogitani Y; Abe Y; Iguchi T; Yamaguchi J; Terauchi T; Kitamura M; Goto K; Goto M; Oitate M; Yukinaga H; Yabe Y; Nakada T; Masuda T; Morita K; Agatsuma T
Bioorg Med Chem Lett; 2016 Oct; 26(20):5069-5072. PubMed ID: 27599744
[TBL] [Abstract][Full Text] [Related]
13. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
[TBL] [Abstract][Full Text] [Related]
14. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition suppresses topoisomerase 1 poisoning induced Caspase-3 dependent cell death in zebrafish embryos.
Tsikarishvili S; Karapetian M; Kulikova N; Zaalishvili G
Biochem Biophys Res Commun; 2021 Apr; 550():166-170. PubMed ID: 33706100
[TBL] [Abstract][Full Text] [Related]
16. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract][Full Text] [Related]
17. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
18. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition.
Berti M; Ray Chaudhuri A; Thangavel S; Gomathinayagam S; Kenig S; Vujanovic M; Odreman F; Glatter T; Graziano S; Mendoza-Maldonado R; Marino F; Lucic B; Biasin V; Gstaiger M; Aebersold R; Sidorova JM; Monnat RJ; Lopes M; Vindigni A
Nat Struct Mol Biol; 2013 Mar; 20(3):347-54. PubMed ID: 23396353
[TBL] [Abstract][Full Text] [Related]
19. Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L; Sadilkova L; Viricel W; Dumontet C
J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
